IN2012DN02485A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02485A IN2012DN02485A IN2485DEN2012A IN2012DN02485A IN 2012DN02485 A IN2012DN02485 A IN 2012DN02485A IN 2485DEN2012 A IN2485DEN2012 A IN 2485DEN2012A IN 2012DN02485 A IN2012DN02485 A IN 2012DN02485A
- Authority
- IN
- India
- Prior art keywords
- rheumatoid arthritis
- methods
- therapeutic agents
- identifying
- diagnosing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27594809P | 2009-09-03 | 2009-09-03 | |
US25242409P | 2009-10-16 | 2009-10-16 | |
PCT/US2010/047734 WO2011028945A1 (fr) | 2009-09-03 | 2010-09-02 | Procédés pour traiter, diagnostiquer, et surveiller la polyarthrite rhumatoïde |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN02485A true IN2012DN02485A (fr) | 2015-08-28 |
Family
ID=43625246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2485DEN2012 IN2012DN02485A (fr) | 2009-09-03 | 2010-09-02 |
Country Status (12)
Country | Link |
---|---|
US (2) | US8728730B2 (fr) |
EP (2) | EP2473637B1 (fr) |
JP (3) | JP5996429B2 (fr) |
KR (1) | KR20120104517A (fr) |
CN (2) | CN107385034B (fr) |
BR (1) | BR112012004777A2 (fr) |
CA (1) | CA2772929A1 (fr) |
HK (1) | HK1245341A1 (fr) |
IN (1) | IN2012DN02485A (fr) |
MX (2) | MX353186B (fr) |
RU (2) | RU2539112C2 (fr) |
WO (1) | WO2011028945A1 (fr) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2380911T1 (en) | 2003-11-05 | 2018-07-31 | Roche Glycart Ag | ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION |
US8645166B2 (en) | 2007-07-16 | 2014-02-04 | Russell W. Bessette | System and method for scoring illness complexity to predict healthcare cost |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
CN107385034B (zh) | 2009-09-03 | 2021-08-17 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗、诊断和监控类风湿性关节炎的方法 |
EP2525822B1 (fr) | 2010-01-20 | 2017-05-10 | Merck Sharp & Dohme Corp. | Immunorégulation par des anticorps anti-ilt5 et fragments d'anticorps se liant à ilt5 |
EP2525813B1 (fr) | 2010-01-20 | 2017-01-04 | Merck Sharp & Dohme Corp. | Anticorps anti-ilt5 et fragments d'anticorps se liant à ilt5 |
MX2012009755A (es) | 2010-02-26 | 2012-09-12 | Novo Nordisk As | Composiciones que contienen anticuerpo estable. |
CA2798432A1 (fr) | 2010-05-06 | 2011-11-10 | Novartis Ag | Compositions et procedes d'utilisation d'anticorps therapeutiques diriges contre la proteine 6 liee a la lipoproteine de basse densite (lrp6) |
CN103237811A (zh) | 2010-05-06 | 2013-08-07 | 诺瓦提斯公司 | 用于治疗性低密度脂蛋白相关蛋白质6(lrp6)多价抗体的组合物及使用方法 |
WO2011147921A1 (fr) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Compositions stables multi-doses comprenant un anticorps et un agent conservateur |
USRE48959E1 (en) | 2010-12-06 | 2022-03-08 | Seagen Inc. | Humanized antibodies to LIV-1 and use of same to treat cancer |
JP5885926B2 (ja) * | 2011-01-28 | 2016-03-16 | シスメックス株式会社 | 関節リウマチの存在の評価方法およびその方法に用いられるバイオマーカーセット |
EP2680884B1 (fr) * | 2011-02-28 | 2018-01-17 | F. Hoffmann-La Roche AG | Marqueurs biologiques et procédés de prédiction de réponse à des antagonistes de lymphocytes b |
MX2014005411A (es) | 2011-11-04 | 2015-02-12 | Novartis Ag | Construcciones prolongadas de la vida media de la proteina relacionada con lipoproteina de baja densidad 6 (lrp6). |
KR20140124767A (ko) | 2012-02-10 | 2014-10-27 | 노보 노르디스크 에이/에스 | 염증성 질환 및 장애의 치료에 관한 방법 |
WO2013135789A1 (fr) * | 2012-03-15 | 2013-09-19 | Universiteit Hasselt | Moyens et procédés pour déterminer la vitesse de progression de la destruction articulaire chez des patients atteints de polyarthrite rhumatoïde (ra) |
WO2013164440A1 (fr) | 2012-05-03 | 2013-11-07 | Novo Nordisk A/S | Procédés relatifs au traitement de maladies et de troubles inflammatoires |
WO2014028374A1 (fr) * | 2012-08-17 | 2014-02-20 | Eli Lilly And Company | Biomarqueurs prédictifs de la réponse de polyarthrite rhumatoïde ou de lupus érythémateux systémique à une thérapie d'anticorps anti-baff |
WO2014118550A1 (fr) * | 2013-01-31 | 2014-08-07 | The University Of Birmingham | Biomarqueurs de maladies auto-immunes et/ou chroniques associées à l'inflammation d'une articulation |
EP2813850A1 (fr) * | 2013-06-10 | 2014-12-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés pour prédire une réponse de traitement de l'arthrite rhumatoïde |
US20160274106A1 (en) * | 2013-06-21 | 2016-09-22 | Catholic University Industry-Academic Cooperation Foundation | Biomarker for rheumatoid arthritis diagnosis or activity evaluation |
TWI725931B (zh) | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗fcrh5抗體 |
CN103399147B (zh) * | 2013-08-07 | 2015-06-17 | 苏州大学 | 多聚半乳糖醛酸的新应用 |
KR101628035B1 (ko) * | 2013-09-13 | 2016-06-09 | 인제대학교 산학협력단 | Vsig4를 이용한 난소암 치료제 스크리닝 방법 |
CN103513040B (zh) * | 2013-10-16 | 2015-03-11 | 常晓天 | 蛋白cd38在制备类风湿性关节炎诊断标记物中的应用 |
EP2863231A1 (fr) * | 2013-10-17 | 2015-04-22 | Institut D'Investigaciones Biomédiques August Pi i Sunyer | Procédé de diagnostic permettant de détecter un GABA(A) associé à une maladie auto-immune et sujet apparenté |
CA2942384C (fr) | 2014-03-12 | 2024-01-23 | Icahn School Of Medicine At Mount Sinai | Procede d'identification de receveurs d'allogreffe de rein a risque de lesion chronique |
RU2554755C1 (ru) * | 2014-05-26 | 2015-06-27 | Федеральное бюджетное учреждение науки "Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера" (ФБУН НИИ эпидемиологии и микробиологии имени Пастера) | Способ диагностики ревматоидного артрита |
ES2850281T3 (es) | 2014-06-26 | 2021-08-26 | Icahn School Med Mount Sinai | Método para diagnosticar el rechazo agudo subclínico y clínico mediante el análisis de conjuntos de genes predictivos, un agente terapéutico para usar en el tratamiento y kits para determinar la expresión |
KR20160048442A (ko) * | 2014-10-24 | 2016-05-04 | 가톨릭대학교 산학협력단 | 류마티스 관절염 관련 바이오마커 |
EP3250925B1 (fr) * | 2015-01-29 | 2019-04-10 | Ares Trading S.A. | Dosages immunologiques de protéines à charge positivement élevée |
CN105988009B (zh) * | 2015-02-28 | 2018-03-13 | 复旦大学附属华山医院 | Netrin‑4在制备检测胃癌及预后标志物的制剂中的用途 |
WO2016154553A1 (fr) * | 2015-03-25 | 2016-09-29 | La Jolla Institute For Allergy And Immunology | Cxcl13 comme indicateur d'activité de centre germinatif et réponse immunitaire |
CA2985637A1 (fr) * | 2015-05-12 | 2016-11-17 | The General Hospital Corporation | Auto-antigenes pour le diagnostic de la polyarthrite rhumatoide |
AU2016280102B2 (en) * | 2015-06-16 | 2022-06-16 | Genentech, Inc. | Humanized and affinity matured antibodies to FcRH5 and methods of use |
CN105200159B (zh) * | 2015-11-06 | 2018-06-15 | 北京致成生物医学科技有限公司 | 骨性关节炎诊疗试剂及其应用 |
GB201521357D0 (en) * | 2015-12-03 | 2016-01-20 | Univ Liverpool | Methods for predicting response to anti-TNF therapy |
MA45324A (fr) | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique |
US11644473B2 (en) * | 2016-04-15 | 2023-05-09 | Rowan University | Serum biomarkers for predicting and evaluating response to TNF inhibitor therapy in rheumatoid arthritis patients |
US20170321286A1 (en) * | 2016-05-05 | 2017-11-09 | Exact Sciences Corporation | Detection of lung neoplasia by amplification of rna sequences |
US10908159B2 (en) | 2016-06-07 | 2021-02-02 | The General Hospital Corporation | Identification of a T cell epitope of Prevotella copri that induces T cell responses in patients with Rheumatoid arthritis |
RU2622597C1 (ru) * | 2016-07-05 | 2017-06-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КубГМУ Минздрава России) | Способ прогнозирования суставного болевого синдрома у пациентов с признаками дисплазии соединительной ткани |
GB201616557D0 (en) * | 2016-09-29 | 2016-11-16 | Secretary Of State For Health The | Assay for distinguishing between sepsis and systemic inflammatory response syndrome |
CN106526196B (zh) * | 2016-10-08 | 2018-08-10 | 北京大学人民医院 | Sr-a作为类风湿关节炎诊断标志物及干预靶点的应用 |
CN110036023B (zh) * | 2016-11-09 | 2023-01-10 | Icm株式会社 | Nkx3.2片段和包含其作为活性成分的药物组合物 |
US11466094B2 (en) | 2016-11-15 | 2022-10-11 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
WO2018164507A2 (fr) * | 2017-03-08 | 2018-09-13 | 주식회사 길로 | Composition productrice de matrice extracellulaire utilisant le gène mast4 et son procédé de préparation |
KR102588627B1 (ko) * | 2017-03-08 | 2023-10-16 | 김성진 | Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법 |
US11325969B2 (en) * | 2017-08-29 | 2022-05-10 | Veritas Therapeutics Inc. | FGL2 antibodies and binding fragments thereof and uses thereof |
CN110268383A (zh) * | 2017-11-13 | 2019-09-20 | 多发性骨髓瘤研究基金会公司 | 综合、分子、组学、免疫疗法、代谢、表观遗传学和临床数据库 |
JP2021511019A (ja) * | 2018-01-24 | 2021-05-06 | ジェネンテック, インコーポレイテッド | 関節リウマチ(ra)の処置のための診断方法及び治療方法 |
CN108359726B (zh) * | 2018-02-28 | 2020-09-04 | 固安博健生物技术有限公司 | Coro2b作为分子诊治标志物的用途 |
EP3765634A4 (fr) | 2018-03-16 | 2021-12-01 | Scipher Medicine Corporation | Méthodes et systèmes de prédiction de la réponse à des thérapies anti-tnf |
CA3095198A1 (fr) | 2018-04-16 | 2019-10-24 | Icahn School Of Medicine At Mount Sinai | Procede et kits pour la prediction d'un rejet aigu et d'une perte d'allogreffe renale a l'aide de signatures transcriptomiques de pre-transplantation dans le sang du receveur |
US20190336585A1 (en) * | 2018-05-03 | 2019-11-07 | John Lawrence Mee | Method for sustainable human cognitive enhancement |
US20190359985A1 (en) * | 2018-05-22 | 2019-11-28 | John Lawrence Mee | Adjustable method for sustainable human cognitive enhancement |
CN109142729B (zh) * | 2018-06-14 | 2021-04-23 | 郑州大学第一附属医院 | 一种肺癌标志物抗-hmgb3自身抗体及其应用 |
US20190390193A1 (en) * | 2018-06-23 | 2019-12-26 | John Lawrence Mee | Reversible method for sustainable human cognitive enhancement |
US10723191B1 (en) | 2018-07-01 | 2020-07-28 | Softwheel Ltd. | In-wheel three-arm suspension for vehicles |
CN110917351A (zh) * | 2018-09-20 | 2020-03-27 | 华中科技大学同济医学院附属同济医院 | Mbd2抑制剂在预防和治疗纤维化疾病中的用途 |
EP3866835B1 (fr) * | 2018-10-19 | 2024-01-03 | The Regents Of The University Of Michigan | Méthode de surveillance d'une maladie auto-immune |
CN109207584A (zh) * | 2018-11-01 | 2019-01-15 | 固安博健生物技术有限公司 | Marco作为早期诊断骨关节炎的分子标志物的应用 |
EP3921335A4 (fr) * | 2019-02-08 | 2023-02-08 | The Regents Of The University Of California | Compositions et méthodes impliquant la layiline |
MX2021013532A (es) * | 2019-05-08 | 2022-02-11 | Janssen Biotech Inc | Materiales y metodos para modular la inmunidad mediada por celulas t. |
MX2022000128A (es) | 2019-06-27 | 2022-04-27 | Scipher Medicine Corp | Desarrollo de clasificadores para estratificar pacientes. |
CN110456074B (zh) * | 2019-08-27 | 2022-06-03 | 广东菲鹏生物有限公司 | 瓜氨酸肽及其应用、类风湿关节炎的检测试剂与试剂盒 |
CN110408590B (zh) * | 2019-09-06 | 2022-10-25 | 遵义医学院附属医院 | 一种诱导人间充质干细胞向成骨细胞分化的方法与应用 |
GB201914079D0 (en) * | 2019-09-30 | 2019-11-13 | Univ London Queen Mary | Method of predicting requirement for biologic therapy |
KR102596937B1 (ko) * | 2019-11-07 | 2023-11-03 | 가톨릭대학교 산학협력단 | 류마티스 관절염의 판누스 진단용 바이오마커 및 이의 이용 |
CN111091909B (zh) * | 2019-11-26 | 2022-05-31 | 中国信息通信研究院 | 一种医学影像识别方法和装置 |
CN113122628B (zh) * | 2019-12-30 | 2023-08-11 | 广州医科大学附属第三医院(广州重症孕产妇救治中心、广州柔济医院) | Clec5a基因作为标志物在子宫内膜癌中诊断及治疗的应用 |
CN112114126B (zh) * | 2020-08-13 | 2023-03-24 | 川北医学院 | 一种系统性红斑狼疮的诊断标志物及其应用 |
WO2022064163A1 (fr) * | 2020-09-22 | 2022-03-31 | The Secretary Of State For Defence | Appareils, kits et procédés pour prédire le développement d'une septicémie |
EP4237003A1 (fr) | 2020-10-28 | 2023-09-06 | Janssen Biotech, Inc. | Compositions et procédés de modulation de l'immunité à médiation par la chaîne gamma delta |
CN112646887B (zh) * | 2020-12-23 | 2023-02-28 | 广州医科大学附属第五医院 | Znf239作为肝癌诊治的靶标 |
CN112946269B (zh) * | 2020-12-29 | 2022-12-27 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | Abca1与cd68作为预后标记物在制备肝癌预后预测试剂盒中的应用 |
CN113186281B (zh) * | 2021-04-02 | 2023-02-28 | 广州医科大学附属第五医院 | 作为肝细胞癌标志物的inava |
CN113512582A (zh) * | 2021-04-15 | 2021-10-19 | 上海鸿准生物医药科技有限公司 | Slc22a18在过敏变态反应性疾病与炎症性疾病中的应用 |
CN113307835B (zh) * | 2021-04-21 | 2022-12-13 | 南通大学 | 一种siRNA及其在制备慢性疼痛治疗药物中的应用 |
EP4356136A1 (fr) * | 2021-06-13 | 2024-04-24 | Technion Research & Development Foundation Limited | Procédé de détermination de l'aptitude à une thérapie anti-tnf alpha |
WO2023158713A1 (fr) * | 2022-02-16 | 2023-08-24 | Ampel Biosolutions, Llc | Procédés d'apprentissage automatique non supervisé |
WO2024108154A2 (fr) * | 2022-11-18 | 2024-05-23 | The United States Government As Represented By The Department Of Veterans Affairs | Procédés de traitement de la polyarthrite rhumatoïde à l'aide d'un inhibiteur de syndécane-1 ou d'un inhibiteur de synténine-1 |
CN117567626B (zh) * | 2024-01-15 | 2024-04-26 | 北京大学人民医院 | 一种抗瓜氨酸化清道夫受体a多肽抗体及其在制备诊断类风湿关节炎的产品中的应用 |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4434227A (en) * | 1982-02-08 | 1984-02-28 | Abbott Laboratories | Immunoassay for class specific immunoglobulin antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
CA1261257A (fr) | 1984-09-19 | 1989-09-26 | Helgi Valdimarsson | Valeur de diagnostic des isotypes du facteur rhumatoide et leur association avec la maladie active |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0814159B1 (fr) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Souris transgéniques capables de produire des anticorps hétérologues |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5484892A (en) * | 1993-05-21 | 1996-01-16 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US6139832A (en) * | 1995-02-08 | 2000-10-31 | Human Genome Sciences, Inc. | Leukocyte adhesion inhibitor-1 (LAI-1) Polypeptides |
WO1996024668A1 (fr) | 1995-02-08 | 1996-08-15 | Human Genome Sciences, Inc. | Chemokine humaine beta-11 et chemokine humaine alpha-1 |
ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JPH11507224A (ja) | 1995-06-05 | 1999-06-29 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | ヒトケモカインβ−11およびヒトケモカインα−1 |
US6254868B1 (en) * | 1996-03-20 | 2001-07-03 | Immunomedics, Inc. | Glycosylated humanized B-cell specific antibodies |
DE69635088T3 (de) | 1996-10-25 | 2012-01-26 | Human Genome Sciences, Inc. | NEUTROKIN alpha |
AU5702298A (en) | 1996-12-03 | 1998-06-29 | Abgenix, Inc. | Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom |
AU5705898A (en) | 1996-12-17 | 1998-07-15 | Schering Corporation | Mammalian cell surface antigens; related reagents |
US6183744B1 (en) * | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
CA2232743A1 (fr) | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | Tl5, homologue tnf |
WO1999012964A2 (fr) | 1997-09-12 | 1999-03-18 | Biogen, Inc. | Kay, nouvelle proteine du systeme immunitaire |
EP1033134B8 (fr) * | 1997-10-29 | 2007-09-19 | Otsuka Pharmaceutical Co., Ltd. | Compositions inhibant la proliferation des muscles lisses et procede de diagnostic de l'arteriosclerose |
US6110695A (en) | 1997-12-02 | 2000-08-29 | The Regents Of The University Of California | Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1 |
AU2093499A (en) | 1997-12-30 | 1999-07-19 | Chiron Corporation | Members of tnf and tnfr families |
JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ATE453712T1 (de) | 1999-01-07 | 2010-01-15 | Zymogenetics Inc | Verfahren zur therapeutischen verwendung von löslichen rezeptoren br43x2 |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
DE60042785D1 (de) | 1999-06-09 | 2009-10-01 | Immunomedics Inc | Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern |
PL207501B1 (pl) | 1999-08-17 | 2010-12-31 | Apotech R & D Sa | Zastosowanie polipeptydu BCMA oraz przeciwciała skierowanego przeciwko BCMA |
DE10041402A1 (de) | 2000-08-23 | 2002-03-14 | Morphochem Ag | Neue Verbindungen, die Faktor Xa-Aktivität inhibieren |
CA2383773A1 (fr) * | 1999-09-01 | 2001-03-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methodes et compositions destinees au traitement des maladies auto-immunes |
US7105149B1 (en) * | 1999-11-29 | 2006-09-12 | The Trustees Of Columbia University In The City Of New York | Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma |
AU2001261557B2 (en) | 2000-05-12 | 2005-06-30 | Amgen Inc. | Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
WO2002002641A1 (fr) | 2000-06-16 | 2002-01-10 | Human Genome Sciences, Inc. | Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b |
WO2002016412A2 (fr) | 2000-08-18 | 2002-02-28 | Dyax Corp. | Polypeptides de liaison pour proteine stimulatrice des lymphocytes b (blys) |
UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
EP1407017B1 (fr) | 2000-11-07 | 2009-06-03 | ZymoGenetics, Inc. | Recepteur humain de facteur de necrose tumorale |
EP2301971A1 (fr) | 2001-02-20 | 2011-03-30 | ZymoGenetics, L.L.C. | Anticorps se liant tant à BCMA qu'à TACI |
US6818406B2 (en) * | 2001-03-23 | 2004-11-16 | Mayo Foundation For Medical Education And Research | Rheumatoid arthritis markers |
DK1385882T3 (da) | 2001-05-11 | 2008-02-11 | Amgen Inc | Peptider og relaterede molekyler, der binder til TALL-1 |
US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
HUP0500992A3 (en) * | 2001-08-03 | 2007-11-28 | Genentech Inc | Tacis and br3 polypeptides and uses thereof |
AU2002330074A1 (en) | 2001-09-21 | 2003-04-01 | Amgen Inc. | Tall-1 receptor molecules and uses thereof |
CA2465268A1 (fr) | 2001-10-24 | 2003-05-01 | National Jewish Medical And Research Center | Structures tridimensionnelles de tall-1 et de ses recepteurs parents, proteines modifiees et procedes associes |
US20050202421A1 (en) * | 2001-10-31 | 2005-09-15 | Raphael Hirsch | Method for diagnosis and treatment of rheumatoid arthritis |
US20030224386A1 (en) * | 2001-12-19 | 2003-12-04 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis |
CN101914158A (zh) | 2002-02-14 | 2010-12-15 | 免疫医疗公司 | 抗cd 20抗体及其融合蛋白和使用方法 |
AU2003215365A1 (en) | 2002-02-21 | 2003-09-09 | Duke University | Treatment methods using anti-cd22 antibodies |
GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
US7258221B2 (en) | 2002-07-18 | 2007-08-21 | Fabio Perini S.P.A. | Storage unit for elongated products |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
BRPI0316779B1 (pt) | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
US6962006B2 (en) | 2002-12-19 | 2005-11-08 | Acusphere, Inc. | Methods and apparatus for making particles using spray dryer and in-line jet mill |
SE0300959D0 (sv) * | 2002-12-19 | 2003-04-02 | Pharmacia Ab | Methods for predicting therapeutic response to agents acting on the growth hormone receptor |
US20050163775A1 (en) | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
ES2538469T3 (es) | 2003-06-05 | 2015-06-22 | Genentech, Inc. | Terapia de combinación para trastornos de células B |
IL156495A0 (en) * | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
JP4711963B2 (ja) * | 2003-09-15 | 2011-06-29 | オクラホマ メディカル リサーチ ファウンデーション | 炎症性疾患および自己免疫疾患を診断、治療および評価するためにサイトカインアッセイを用いる方法 |
DE102004016437A1 (de) * | 2004-04-04 | 2005-10-20 | Oligene Gmbh | Verfahren zur Erkennung von Signaturen in komplexen Genexpressionsprofilen |
CA2501422C (fr) * | 2004-04-29 | 2014-08-12 | University Of Rochester | Chimiokines lymphoides dans le diagnostic, la surveillance et le traitement de maladies auto-immunes |
SV2006002131A (es) | 2004-06-04 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento de lupus |
WO2006039238A2 (fr) | 2004-09-30 | 2006-04-13 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anticorps de irta2 et méthodes d'utilisation |
CN101087807A (zh) | 2004-10-05 | 2007-12-12 | 健泰科生物技术公司 | 治疗血管炎的方法 |
EP1907858A4 (fr) * | 2005-06-13 | 2009-04-08 | Univ Michigan | Compositions et procedes de traitement et de diagnostic du cancer |
US20080213273A1 (en) * | 2005-07-25 | 2008-09-04 | Trubion Pharmaceuticals Inc. | Single dose use of CD20-specific binding molecules |
ZA200801354B (en) * | 2005-08-09 | 2009-08-26 | Ares Trading Sa | Methods for treating B-cell malignancies using TACI-lg fusion molecule |
EP1945814A2 (fr) * | 2005-09-27 | 2008-07-23 | Source MDX | Profilage d'expression génique aux fins de surveillance de l'identification et de traitement de la polyarthrite rhumatoïde |
WO2007038501A2 (fr) | 2005-09-27 | 2007-04-05 | The Feinstein Institute For Medical Research | Marqueurs de l'arthrite rhumatoide |
US20090128815A1 (en) | 2006-03-15 | 2009-05-21 | Koninklijke Philips Electronics N.V. | Remote control pointing technology with roll detection |
GB0607774D0 (en) | 2006-04-20 | 2006-05-31 | Renovo Group Plc | Medicaments |
WO2007124414A2 (fr) | 2006-04-21 | 2007-11-01 | Centocor, Inc. | Antagonistes de cxcl13 et leur utilisation pour le traitement de maladies inflammatoires |
US20080227655A1 (en) * | 2006-05-16 | 2008-09-18 | Michael Bevilacqua | Assessment of effect of an agent on a human biological condition using rodent gene expression panels |
EP1857559A1 (fr) | 2006-05-16 | 2007-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthode de prédiction de la réponse aux agents de blocage de TNF aplha |
US20070269827A1 (en) * | 2006-05-18 | 2007-11-22 | Oklahoma Medical Research Foundation | Predicting and Diagnosing Patients With Autoimmune Disease |
WO2008156494A1 (fr) * | 2006-11-03 | 2008-12-24 | The Johns Hopkins University | Utilisation de médicaments d'oxazaphosphorine à dose élevée en combinaison avec des anticorps monoclonaux pour le traitement de troubles immunitaires |
CA2668955A1 (fr) | 2006-11-09 | 2008-05-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Procede permettant de predire la sensibilite therapeutique a des agents bloquant le tnf-alpha |
US20080227704A1 (en) * | 2006-12-21 | 2008-09-18 | Kamens Joanne S | CXCL13 binding proteins |
US20080199481A1 (en) | 2007-02-21 | 2008-08-21 | Astrazeneca Ab | Compounds |
US20100273671A1 (en) | 2007-03-01 | 2010-10-28 | Universite Catholique De Louvain | Method for the determination and the classification of rheumatic conditions |
JP2010523580A (ja) | 2007-03-30 | 2010-07-15 | セントコア・オーソ・バイオテツク・インコーポレーテツド | Cxcl13アンタゴニストおよび炎症性疾患の処置のためのそれらの使用 |
CN101711286A (zh) * | 2007-04-02 | 2010-05-19 | 健泰科生物技术公司 | 预示类风湿性关节炎对b细胞拮抗剂的响应的生物学标志物 |
WO2008132176A2 (fr) | 2007-04-27 | 2008-11-06 | Universite Catholique De Louvain | Méthode de prévision de la réponse d'un patient à une thérapie bloquant le tnf |
NZ581742A (en) | 2007-06-08 | 2012-09-28 | Biogen Idec Inc | Biomarkers for predicting anti-tnf responsiveness or non-responsiveness |
CA2698437A1 (fr) * | 2007-09-03 | 2009-03-12 | Protagen Ag | Sequences de marqueurs de la polyarthrite rhumatoide et leur utilisation |
US20090202474A1 (en) * | 2007-11-19 | 2009-08-13 | Wyeth | Expression of orphan gpr64 in inflammatory diseases |
US8121883B2 (en) * | 2008-02-07 | 2012-02-21 | International Business Machines Corporation | Method and system for automatically prioritizing opportunity based customer requirements |
AU2010236787A1 (en) | 2009-04-01 | 2011-11-10 | Genentech, Inc. | Anti-FcRH5 antibodies and immunoconjugates and methods of use |
CN107385034B (zh) | 2009-09-03 | 2021-08-17 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗、诊断和监控类风湿性关节炎的方法 |
-
2010
- 2010-09-02 CN CN201710584303.6A patent/CN107385034B/zh active Active
- 2010-09-02 EP EP10814522.8A patent/EP2473637B1/fr active Active
- 2010-09-02 CN CN201080049387.XA patent/CN102597268B/zh active Active
- 2010-09-02 MX MX2014012257A patent/MX353186B/es unknown
- 2010-09-02 KR KR1020127008453A patent/KR20120104517A/ko not_active Application Discontinuation
- 2010-09-02 BR BR112012004777A patent/BR112012004777A2/pt not_active IP Right Cessation
- 2010-09-02 US US12/874,972 patent/US8728730B2/en active Active
- 2010-09-02 EP EP16203656.0A patent/EP3211094A3/fr not_active Withdrawn
- 2010-09-02 MX MX2012002766A patent/MX2012002766A/es active IP Right Grant
- 2010-09-02 RU RU2012112822/10A patent/RU2539112C2/ru not_active IP Right Cessation
- 2010-09-02 IN IN2485DEN2012 patent/IN2012DN02485A/en unknown
- 2010-09-02 WO PCT/US2010/047734 patent/WO2011028945A1/fr active Application Filing
- 2010-09-02 JP JP2012528063A patent/JP5996429B2/ja active Active
- 2010-09-02 CA CA2772929A patent/CA2772929A1/fr not_active Abandoned
-
2014
- 2014-04-08 US US14/248,135 patent/US9822400B2/en active Active
- 2014-11-06 RU RU2014145058A patent/RU2014145058A/ru not_active Application Discontinuation
-
2016
- 2016-06-23 JP JP2016124696A patent/JP6895718B2/ja active Active
-
2018
- 2018-04-03 HK HK18104432.8A patent/HK1245341A1/zh unknown
-
2020
- 2020-09-23 JP JP2020158134A patent/JP2021019594A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MX353186B (es) | 2018-01-05 |
JP6895718B2 (ja) | 2021-06-30 |
CN102597268B (zh) | 2017-09-22 |
JP2021019594A (ja) | 2021-02-18 |
CN107385034A (zh) | 2017-11-24 |
US20140341887A1 (en) | 2014-11-20 |
JP2017000141A (ja) | 2017-01-05 |
US8728730B2 (en) | 2014-05-20 |
EP2473637A4 (fr) | 2013-05-01 |
JP2013503643A (ja) | 2013-02-04 |
MX2012002766A (es) | 2012-04-02 |
CN107385034B (zh) | 2021-08-17 |
US9822400B2 (en) | 2017-11-21 |
US20110052488A1 (en) | 2011-03-03 |
RU2014145058A (ru) | 2016-05-27 |
BR112012004777A2 (pt) | 2019-09-24 |
WO2011028945A1 (fr) | 2011-03-10 |
RU2539112C2 (ru) | 2015-01-10 |
RU2012112822A (ru) | 2013-10-10 |
CA2772929A1 (fr) | 2011-03-11 |
CN102597268A (zh) | 2012-07-18 |
EP2473637B1 (fr) | 2017-03-29 |
JP5996429B2 (ja) | 2016-09-21 |
KR20120104517A (ko) | 2012-09-21 |
EP3211094A2 (fr) | 2017-08-30 |
HK1245341A1 (zh) | 2018-08-24 |
EP2473637A1 (fr) | 2012-07-11 |
EP3211094A3 (fr) | 2017-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN02485A (fr) | ||
PH12018500045A1 (en) | Compositions and methods for treating and diagnosing asthma | |
MX353143B (es) | Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b. | |
WO2010036960A3 (fr) | Procédés pour traiter, diagnostiquer, et surveiller le lupus | |
JO3131B1 (ar) | مركبات كيميائية | |
EA201390762A1 (ru) | Новые биомаркеры для предсказания исхода противораковой иммунотерапии | |
EA201291107A1 (ru) | Соединения, ингибирующие металлоферменты | |
EP2373784A4 (fr) | Génération et entretien de cellules souches | |
AU2011260390A8 (en) | Means and methods for diagnosing pancreatic cancer in a subject | |
WO2012106718A3 (fr) | Procédés d'utilisation de signatures d'expression génique pour sélectionner un procédé de traitement, prédire un pronostic, la survie, et/ou prédire une réponse à un traitement | |
TR201901930T4 (tr) | Topraktaki mikrobiyal aktivitenin geliştirilmesine yönelik bir yöntem. | |
EA201491151A1 (ru) | Соединения, ингибирующие металлоферменты | |
TN2013000464A1 (en) | Biomarkers for hedgehog inhibitor therapy | |
EA201390704A1 (ru) | Соединения, ингибирующие металлоферменты | |
MX358541B (es) | Metodos para predecir el riesgo de desarrollar hipertension. | |
MX2010005395A (es) | Metodo para tratar artritis. | |
WO2011088137A3 (fr) | Signature de gènes impliqués dans la transduction du signal bad | |
EP2516624A4 (fr) | Lignée cellulaire 3m | |
MX337203B (es) | Novedosas moleculas inhbidoras de jnk. | |
BR112015013771A2 (pt) | biomarcador preditivo de resposta ao tratamento de ativador do receptor alfa 7 nicotínico de acetilcolina | |
IN2012DN00852A (fr) | ||
EP2488187A4 (fr) | Dosage permettant de prédire l'efficacité thérapeutique de cellules stromales mésenchymateuses, et ses procédés d'utilisation | |
MX357429B (es) | Predictores para el tratamiento del cáncer. | |
MX2013011334A (es) | Biomarcadores para pronosticar sensibilidad a tratamientos contra el cancer. | |
EP3839068A3 (fr) | Procédés pour traiter, diagnostiquer, et surveiller le lupus |